Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and Worsens the prognosis of patients with advanced head and neck cancer

PloS One
Takeichiro AsoMuneyuki Masuda

Abstract

At our institute, a chemoradioselection strategy has been used to select patients for organ preservation on the basis of response to an initial 30-40 Gy concurrent chemoradiotherapy (CCRT). Patients with a favorable response (i.e., chemoradioselected; CRS) have demonstrated better outcomes than those with an unfavorable response (i.e., nonchemoradioselected; N-CRS). Successful targeting of molecules that attenuate the efficacy of chmoradioselection may improve results. Thus, the aim of this study was to evaluate the association of a novel cancer stem cell (CSC) marker, CD44 variant 9 (CD44v9), with cellular refractoriness to chemoradioselection in advanced head and neck squamous cell carcinoma (HNSCC). Through a medical chart search, 102 patients with advanced HNSCC treated with chemoradioselection from 1997 to 2008 were enrolled. According to our algorithm, 30 patients were CRC following induction CCRT and 72 patients were N-CRS. Using the conventional immunohistochemical technique, biopsy specimens and surgically removed tumor specimens were immunostained with the anti-CD44v9 specific antibodies. The intrinsic expression levels of CD44v9 in the biopsy specimens did not correlate with the chemoradioselection and patient surviv...Continue Reading

References

Dec 3, 2003·The New England Journal of Medicine·Arlene A ForastiereJay Cooper
Mar 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Athanassios ArgirisEverett E Vokes
Dec 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan UrbaJeremy Taylor
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J AdelsteinMarjorie A Carroll
Jan 11, 2007·Proceedings of the National Academy of Sciences of the United States of America·M E PrinceL E Ailles
Oct 26, 2007·The New England Journal of Medicine·Jan B VermorkenUNKNOWN EORTC 24971/TAX 323 Study Group
Oct 26, 2007·The New England Journal of Medicine·Marshall R PosnerUNKNOWN TAX 324 Study Group
May 14, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francis P WordenThomas E Carey
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitchell MachtayK Kian Ang
Oct 15, 2008·PloS One·Brigitte Mack, Olivier Gires
Mar 6, 2010·The Lancet Oncology·June CorryDanny Rischin
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M R Posner
Nov 26, 2010·Cancer Research·Sudha KrishnamurthyJacques E Nör
Dec 17, 2010·Nature Reviews. Cancer·C René LeemansRuud H Brakenhoff
Jun 19, 2012·Cell Stem Cell·Jane E Visvader, Geoffrey J Lindeman
Jul 10, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Se-Yeong OhYoung Chang Lim
Nov 22, 2012·Molecular Oncology·Muneyuki MasudaAndrew K Joe
Feb 7, 2013·Medicina oral, patología oral y cirugía bucal·Shao-Hui Huang, Brian O'Sullivan
Apr 30, 2013·PloS One·Takayuki ImaiNobuyuki Tanaka

❮ Previous
Next ❯

Citations

May 21, 2016·Stem Cells International·Ranjeeta Thapa, George D Wilson
Sep 6, 2019·Journal of Cancer Research and Clinical Oncology·Hirofumi OmoriMuneyuki Masuda
Mar 20, 2018·Oncology Letters·Bo HuJinfeng Chen
Feb 9, 2019·Tissue Engineering. Part a·Chiharu SogawaKen-Ichi Kozaki
Jul 5, 2018·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Eriko TokunagaMayumi Ishida
Jul 31, 2019·Cellular Signalling·Spyros S SkandalisNikos K Karamanos
May 9, 2021·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Tomoko JogoMasaki Mori

❮ Previous
Next ❯